Laiba Immad
2 min read
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best small cap pharma stocks to buy right now.
TheFly reported on May 13 that BIOA received newly initiated coverage with a Buy rating and a $40 price target by BITG. The company is described as a clinical-stage biopharmaceutical firm targeting diseases associated with human aging through analysis of large human datasets to identify biological markers that influence long-term health outcomes. The outlook highlights a roughly four-year cash runway and upcoming clinical catalysts, including BGE-102 expected in the second half of 2026 and BGE-105 anticipated in mid-2027. The lead cardiovascular risk program is viewed as biologically de-risked based on evidence linking reductions in systemic inflammation with improved clinical outcomes, supporting the firm’s positive stance on the development pipeline.
Additionally, on May 8, BioAge Labs, Inc. (NASDAQ:BIOA) reported first-quarter 2026 financial results for the period ended March 31, 2026, alongside a business update. Collaboration revenue increased to $2.8 million from $1.5 million a year earlier, driven by higher activity under its Novartis agreement.
Research and development expenses rose to $20.4 million, reflecting increased spending on the BGE-102 program, including late-stage Phase 1 completion work, preparation for upcoming Phase 2 cardiovascular risk studies, and expansion into additional proof-of-concept trials. Additional R&D costs were driven by other pipeline programs and manufacturing efforts. General and administrative expenses increased to $7.7 million due to higher personnel costs and legal expenses. Net loss widened to $22.3 million, while cash reserves stood at approximately $384.9 million, supporting operations through 2029.
BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company developing therapies for metabolic and age-related diseases by targeting the biological drivers of aging.
While we acknowledge the potential of BIOA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
